专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120195924A1 ADENOVIRAL VECTOR VACCINE 有权
公开(公告)号：US20120195924A1
公开(公告)日：2012-08-02
申请号：US13364370
申请日：2012-02-02
申请人： Albert B. Deisseroth , Lixin Zhang
发明人： Albert B. Deisseroth , Lixin Zhang
IPC分类号： A61K39/12 , A61P37/04
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/575 , C07K14/005 , C07K14/70575 , C07K14/70578 , C07K2319/02 , C07K2319/40 , C07K2319/74 , C12N15/86 , C12N2710/10343 , C12N2710/10371 , C12N2710/20022 , C12N2710/20034 , C12N2710/20071
摘要： Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
摘要翻译：提供用于产生对抗原的免疫应答的腺病毒载体。载体包含编码可分泌多肽的转录单元，该多肽包含在CD40配体上游的肿瘤抗原上游的分泌信号序列，其缺失所有或基本上所有的跨膜结构域再现CD40L可分泌。还提供了通过施用有效量的本发明载体产生针对表达肿瘤抗原的细胞的免疫应答的方法。还提供了通过施用有效量的本发明载体产生针对表达个体肿瘤抗原的癌症的免疫应答的方法。还提供了通过施用有效量的本发明的针对HPV的E6或E7蛋白的本发明载体来产生人乳头瘤病毒（HPV）感染免疫的方法。产生的免疫力是长期的。

2. 发明授权

US10835589B2 Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD40L/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells 有权
公开(公告)号：US10835589B2
公开(公告)日：2020-11-17
申请号：US16507432
申请日：2019-07-10
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/02 , A61K39/39 , A61K39/00
CPC分类号： A61K39/0208 , A61K39/39 , A61K2039/5256 , A61K2039/572 , A61K2039/6031 , C12N2710/10343
摘要： A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.

3. 发明申请

US20170239339A1 VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1d RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS 审中-公开
公开(公告)号：US20170239339A1
公开(公告)日：2017-08-24
申请号：US15138511
申请日：2016-04-26
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/02 , A61K39/39 , C12N7/00
CPC分类号： A61K39/0208 , A61K39/0011 , A61K39/39 , A61K39/39541 , A61K2039/5256 , A61K2039/572 , A61K2039/6031 , C12N2710/10343
摘要： A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.

4. 发明授权

US10130667B1 TAA/ecdCD40L oncolytic virus 有权
公开(公告)号：US10130667B1
公开(公告)日：2018-11-20
申请号：US15130041
申请日：2016-04-15
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K35/761 , A61K48/00 , C12N7/00 , A61K38/16 , A61K9/00 , A61K31/513 , A61K38/50 , A61K39/00 , C12N15/861 , C07K14/005
摘要： The present invention relates to a vaccine comprising the insertion of three genes, the TAA/ecdCD40L EA1 and CDA, driven by promoters L-plastin/cytosinedeaminase and CMV as a three gene, three transcription unit oncolytic virus as a conditionally replication competent adenoviral vector which replicates only in tumor cells. In these transcription units, the E1A gene of the adenoviral vector as well as the cytosine deaminase gene are under the control of the L-plastin promoter, while the TAA/ecdCD40L transcription unit is under control of a the CMV promoter.

5. 发明申请

US20140127252A1 TULAREMIA-TAA/CD40L VACCINE 审中-公开
标题翻译： TULAREMIA-TAA / CD40L疫苗
公开(公告)号：US20140127252A1
公开(公告)日：2014-05-08
申请号：US14154710
申请日：2014-01-14
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/02
CPC分类号： A61K39/0208 , A61K2039/53 , C07K14/005 , C07K2319/06 , C07K2319/33
摘要： A Tularemia vaccine proposes to induce antibodies which through their binding to the target proteins of the vaccine strategy will inactivate the proteins essential to mediating the secretory function of the pilus proteins of the “type IV pilus proteins” or Tfp proteins, thereby impairing the formation of the pilus proteins on the surface of the FT which are needed for binding and entry of the FT into macrophages, and will inhibit the secretion of several factors of FT which are necessary for the virulence of the FT, and which are missing in attenuated strains of FT used in current attenuate strain vaccination strategies. The vaccine may be a mixture of DNA plasmids encoding TAA/ecdCD4OL protein vaccines in which the TAA is comprised of fragments of the following Tularemia proteins: Tfp, pilA, pilC, pilT, and pilQ,
摘要翻译：图雷雷米亚疫苗提出诱导抗体，通过它们与疫苗策略的靶蛋白的结合将使对介导“IV型绒毛蛋白”或Tfp蛋白的菌毛蛋白的分泌功能至关重要的蛋白质失活，从而损害了在FT的表面上的FT的表面上的真菌蛋白质是FT结合并进入巨噬细胞所必需的，并且将抑制FT的毒性所必需的几种FT因子的分泌，并且其在减毒菌株中缺失 FT用于目前的减毒疫苗接种策略。疫苗可以是编码TAA / ecdCD4OL蛋白疫苗的DNA质粒的混合物，其中TAA由以下Tularemia蛋白质的片段组成：Tfp，pilA，pilC，pilT和pilQ，

6. 发明申请

US20200046820A1 VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1d RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS 审中-公开
公开(公告)号：US20200046820A1
公开(公告)日：2020-02-13
申请号：US16507432
申请日：2019-07-10
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/02 , A61K39/39
摘要： A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.

7. 发明授权

US10383932B2 Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells 有权
公开(公告)号：US10383932B2
公开(公告)日：2019-08-20
申请号：US15138511
申请日：2016-04-26
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/02 , A61K39/39 , A61K39/00
摘要： A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.

8. 发明授权

US10149899B1 Composition and method against C-difficile 有权
公开(公告)号：US10149899B1
公开(公告)日：2018-12-11
申请号：US15375455
申请日：2016-12-12
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/08 , C12N9/10 , C07K14/705 , A61K39/00
摘要： This two-step method used in the Clostridium difficile toxin transport is a unique method of delivery. The use of a vaccine (TAA/ecdCD40L) for the interdiction of this two-step delivery toxin system to reduce cell death and the death of human subjects is believed to be unique in the area of neutralizing antibodies for protection against the lethal effects of an infectious agent. The proposed composition/vaccine strategy for C difficile is to combine and administer at the same time the two compositions/vaccines for Toxin A, the one composition/vaccine for Toxin B and the one vaccine for CDTb to determine the effect of mixing these compositions/vaccines on protecting mice from a lethal dose of C difficile. This is believed to be the first time that two different tandem repeats from the contact of a ligand with its cellular receptor have been used to prevent binding of the ligand to its cellular receptor.

9. 发明授权

US09889188B1 Ebola virus composition/vaccine 有权
公开(公告)号：US09889188B1
公开(公告)日：2018-02-13
申请号：US15341389
申请日：2016-11-02
申请人： Albert B. Deisseroth
发明人： Albert B. Deisseroth
IPC分类号： A61K39/395 , C07K16/28 , C07K16/00 , G01N33/53 , A61K45/06 , A61K39/12 , C12N7/00 , C07K14/005 , C07K14/705 , A61K39/00
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/54 , A61K2039/57 , A61K2039/575 , C07K14/005 , C07K14/70575 , C07K2319/40 , C12N7/00 , C12N2710/10043 , C12N2760/14122 , C12N2760/14134 , C12N2760/14171
摘要： The present invention is directed to a composition and/or plasmid and/or vector vaccine which encodes four fragments of the GP1 Ebola protein attached to the extracellular domain of the potent immunostimulatory protein CD40 ligand, in the configuration of two compositions and/or vaccines that are mixed together, to respectively increase the levels of antibodies and CD8 effector T cells, against the lethal Ebola virus.

10. 发明申请

US20140080208A1 ADENOVIRAL VECTOR VACCINE 有权
公开(公告)号：US20140080208A1
公开(公告)日：2014-03-20
申请号：US13974353
申请日：2013-08-23
申请人： Albert B. Deisseroth , Lixin Zhang
发明人： Albert B. Deisseroth , Lixin Zhang
IPC分类号： C07K14/705 , C07K14/005
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/575 , C07K14/005 , C07K14/70575 , C07K14/70578 , C07K2319/02 , C07K2319/40 , C07K2319/74 , C12N15/86 , C12N2710/10343 , C12N2710/10371 , C12N2710/20022 , C12N2710/20034 , C12N2710/20071
摘要： Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
摘要翻译：提供用于产生对抗原的免疫应答的腺病毒载体。载体包含编码可分泌多肽的转录单元，该多肽包含在CD40配体上游的肿瘤抗原上游的分泌信号序列，其缺失所有或基本上所有的跨膜结构域再现CD40L可分泌。还提供了通过施用有效量的本发明载体产生针对表达肿瘤抗原的细胞的免疫应答的方法。还提供了通过施用有效量的本发明载体产生针对表达个体肿瘤抗原的癌症的免疫应答的方法。还提供了通过施用有效量的编码HPV的E6或E7蛋白的本发明载体来产生人乳头瘤病毒（HPV）感染免疫的方法。产生的免疫力是长期的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式